Furthermore, we observed neither MEK1 mutations nor MEK1 CNVs in ACC, UCS, UVM, DLBC, acute myeloid leukemia (AML), GBM, renal papillary cell carcinoma (PRCC), LGG and PAAD (Fig. 6A). This evidence concerns the gene MAP2K1 and papillary renal cell carcinoma.